The approval was based on the TRuE-AD3 trial, which evaluated the safety and efficacy of ruxolitinib in pediatric patients aged 2 to 11 years with atopic dermatitis.

HealthDay News — The US Food and Drug Administration (FDA) has approved Opzelura cream 1.5% (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD).

Gout was associated with a 30% higher risk for chronic opioid exposure based on US Veteran's Health Administration data. Patients with gout in the United States are at greater risk for chronic opioid ...

About 80% of parents currently choose to follow CDC guidelines to vaccinate their babies for hepatitis B at birth.

Private equity hospitals reduced ED and ICU salary expenditures after acquisition relative to control hospitals .

HealthDay News — People living with type 2 diabetes experience double the risk for incident sepsis versus matched individuals without diabetes, according to a study presented at the annual meeting of ...

Researchers assessed whether a childhood asthma subgroup at high-risk for ARI could be identified using natural language processing algorithms as a “digital biomarker.” ...

In a prospective cohort study, researchers examined how early life medical risk factors for individuals born preterm compare with those born full-term in adulthood.

Researchers examined the association between levels of vitamin D and risk for MS among White and Black military personnel in the US.

Utah has reported 27 cases so far; Arizona has 42 confirmed cases, including 1 child who has been hospitalized.

HealthDay News — Psilocybin-assisted therapy (PAT) shows long-term safety and efficacy for treating symptoms of major depressive disorder (MDD), according to a study published in the Journal of ...

HealthDay News — During August 2021 to August 2023, only 36.4% of US adults had no cardiovascular disease (CVD) risk factors, according to a September data brief published by the National Center for ...